A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC) - Shen, Lin; Ananda, Sumitra; Cao, Dan; Han, Catherine HyeWon; Coward, Jermaine; Chao, Yee; Li, Wei; Hari Dass, Prashanth; Hsu, Chih-Hung; Nagrial, Adnan; Huang, Yuan; Ganju, Vinod; et al. (Journal of clinical oncology, 2024)